offer
all report title image
  • Published On : Aug 2022
  • Code : CMI1006
  • Industry : Pharmaceutical
  • Pages : 175
  • Formats :

Actinic Keratosis is a damage caused to skin due to excessive sun exposure. Actinic Keratosis is a very common precursor to skin cancer. Actinic keratosis is considered a chronic disorder, where the majority of patients experience recurrent lesions over time. Actinic keratosis increases the risk of developing skin cancer, as it may develop into squamous cell carcinoma (SCC), a common and sometimes invasive skin cancer. Actinic keratosis is an early precursor to squamous cell carcinoma, a malignant skin tumor that develops from the keratinizing cells (keratinocytes) in the epidermis or skin adnexa. Due to the risk that actinic keratosis may develop into SCC, treatment is generally recommended. The disease is mainly treated repeatedly with cryotherapy, photodynamic therapy or topical agents.

Global Actinic Keratosis Market - Impact of the Coronavirus (COVID-19) Pandemic

COVID-19 Pandemic has impacted all the business sectors. Healthcare sector has also been impacted by the COVID-19. The coronavirus or COVID-19 outbreak started in Wuhan, China in 2019 and has spread across all the continents of the world, affecting various industries globally. The economy in countries all over the world such as India, Italy, Bangladesh, Sri Lanka, the U.S., Morocco, and others have been disrupted due to lockdowns implemented by governments to combat the spread of coronavirus since 2020. According to an article published in September 2021 by the Department of Dermatology and Venereology, Bozok and University Faculty of Medicine, Yozgat, Turkey, during the pandemic, the coronavirus had a negative impact on dermatological outpatient clinics as the public was advised not to visit hospitals and outpatient clinics because the primary focus was on providing medical care for COVID-19 patients and controlling the spread of the virus. This study examined the frequency, profile, and diagnostic spectrum of dermatology patients during the pandemic in 2019 to identify the impact of the pandemic. According to a study published in January 2021 by the National Center for Biotechnology Information (NCBI) on the impact of the COVID-19 pandemic on dermatology practice around the world, the COVID outbreak had a negative impact on most dermatology services, with a significant reduction in consultation time spent for chronic patients and a higher risk of missed melanoma and no melanoma skin cancer (NMSC) diagnosis.

Global actinic keratosis market is estimated to be valued at US$ 8,070.0 Mn in 2022 and expected to exhibit a CAGR of 4.7% over the forecast period (2022-2030).

Figure 1: Global Actinic Keratosis Market Share (%) Analysis, By Treatment, 2022

Actinic Keratosis  | Coherent Market Insights

High efficiency of actinic keratosis treatment is expected to drive growth of global actinic keratosis market over the forecast period.

High efficiency of actinic keratosis treatment is expected to be the major factor driving growth of the actinic keratosis market over the forecast period. For instance, according to an article published in the Australian Family Physician journal, a monthly peer-reviewed medical journal, in May 2017, it was estimated that cryosurgery treatment for actinic keratosis has an efficiency between 86% and 99%.

Moreover, a number of treatments for actinic keratosis are available globally, which gives different choices to patients. This is expected to further boost the global actinic keratosis market growth. According to data published by Biofrontera AG Investor Presentation in January 2020, most dermatologists in the U.S. have traditionally preferred cryotherapy for the treatment of actinic keratosis due to more favorable monetary reimbursement whereas dermatologists in Europe have favored topical prescriptions such as fluorouracil, ingenol mebutate, and others due to the lack of reimbursement for procedures such as photodynamic therapy.

Increasing number of product approvals for the treatment of actinic keratosis from regulatory bodies is expected to drive the growth of global actinic keratosis market over the forecast period.

Actinic keratosis market is expected to witness significant growth over the forecast period, owing to increasing focus of market players on gaining product approvals for the treatment of actinic keratosis from regulatory bodies. For instance, in March 2020, Biofrontera AG, a Germany-based pharmaceutical company, announced that it had received approval from the European Commission for the use of its drug Ameluz, in combination with photodynamic therapy for the treatment of adults suffering from actinic keratosis on the extremities and trunk/neck in Europe.

CMI table icon

Actinic Keratosis Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 8,070.0 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 4.7% 2030 Value Projection: US$ 11,628.0 Mn
Geographies covered:
  • Region: North America, Latin America, Europe, Asia Pacific, Middle East, Africa
Segments covered:
  • By Treatment: Medication, Surgical Procedure (Chemical peel, Cryosurgery, Curettage and desiccation, Laser surgery), Photodynamic Therapy, Combination Therapies(Cryosurgery and PDT, Cryosurgery and a topical treatment, Topical treatment and PD)
  • By End User: Hospitals & Specialty Clinics, Homecare
Companies covered:

Almirall, S.A., Bausch Health Companies Inc., Perrigo Company plc., Sun Pharmaceutical Industries Ltd., Hill Dermaceuticals, Inc., Spear Pharmaceuticals, Tolmar Pharmaceuticals, Inc., Bioforntera AG, Cipher Pharmaceuticals Inc., Vidac, Athenex, Inc., 3M, and Mayne Pharma Group Limited.

Growth Drivers:
  • High efficiency of actinic keratosis treatment
  • Increasing product approvals from regulatory bodies
Restraints & Challenges:
  • Side effects of actinic keratosis drugs

  

Global Actinic Keratosis Market – Restraints

Global actinic keratosis market growth is expected to be hampered in the near future, owing to side effects of the drugs prescribed for actinic keratosis.

Some of the common side effects of actinic keratosis drugs are:

  • Burning or crusting
  • Redness or discoloration
  • Irritation and pain
  • Itching and rash
  • Soreness

Some of the serious side effects of actinic keratosis drugs are:

  • Severe stomach ache
  • Blood in diarrhea
  • Vomiting
  • Fever and chills
  • Severe red skin rashes

Global Actinic Keratosis Market – Region Analysis

On the basis of region, global actinic keratosis market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East and Africa.

North America is expected to hold a dominant position in the market during the forecast period, owing to increasing number of product approvals for the treatment of actinic keratosis from regulatory bodies by market key players in the region. For instance, in December 2020, Almirall, S.A, a Spain-based pharmaceutical company, announced that it had received the U.S. Food and Drug Administration (FDA) approval for its drug Klisyri (tirbanibulin) indicated for the treatment of actinic keratosis of the face and scalp in adults.

Figure 2: Global Actinic Keratosis Market (US$ Mn), by Region, 2022

Actinic Keratosis  | Coherent Market Insights

Global Actinic Keratosis Market – Competitive Landscape

Major players operating in global actinic kertosis market include Almirall, S.A., Bausch Health Companies Inc., Perrigo Company plc., Sun Pharmaceutical Industries Ltd., Hill Dermaceuticals, Inc., Spear Pharmaceuticals, Tolmar Pharmaceuticals, Inc., Bioforntera AG, Cipher Pharmaceuticals Inc., Vidac, Athenex, Inc., 3M, and Mayne Pharma Group Limited.

Actinic Keratosis (AK) is the most common pre-cancer that forms on skin damaged by chronic exposure to ultraviolet (UV) rays from the sun. Actinic Keratosis is also known as solar keratosis. Actinic keratosis forms like a patch on the skin. The patches usually appear on areas of your body that are often exposed to the sun, such as your face, hands and arms, ears, scalp and legs. Sometimes actinic keratosis can turn into squamous cell skin cancer. For this reason, the lesions are often called pre-cancer. Patches are not life-threatening. But if patches are found and treated early, they do not have the chance to develop into skin cancer. Actinic Keratosis can affect:

  • People with pale skin, blonde or red hair, and blue, green, or gray eyes
  • People with darker skin, hair, and eyes who have been exposed to UV rays without protection
  • Older adults
  • People with suppressed immune systems (due to chemotherapy, AIDS, organ transplant, or other causes)
  • People with rare conditions that make the skin very sensitive to UV rays, such as albinism or xeroderma pigmentosum (XP)

Market Dynamics

Increasing number of drug approvals for the treatment of actinic keratosis from regulatory bodies is expected to drive growth of the global actinic keratosis market during the forecast period. For instance, In November 2017, Perrigo Company plc, an Ireland based healthcare company, had announced that the company had received tentative approval from the U.S. Food and Drug Administration (FDA) for the generic version of Picato Gel (ingenol mebutate) 0.05%. It is indicated for the topical treatment of actinic keratosis.

High incidence rate of skin cancer is expected to drive growth of the global actinic keratosis market. For instance, according to American Academy of Dermatology Association 2022, Skin cancer is the most common cancer in the U.S. It is estimated that approximately 9,500 people in the U.S. are diagnosed with skin cancer every day. It is estimated that the overall incidence of basal cell carcinoma (BCC) increased by 145% between 1976-1984 and between 2000-2010, and the overall incidence of squamous cell carcinoma (SCC) increased 263% over that same period.

Key features of the study:

  • This report provides an in-depth analysis of global actinic keratosis market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global actinic keratosis market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
  • Key companies covered as a part of this study include Almirall, S.A., Bausch Health Companies Inc., Perrigo Company plc., Sun Pharmaceutical Industries Ltd., Hill Dermaceuticals Inc., Spear Pharmaceuticals, Tolmar Pharmaceuticals Inc., Biofrontera AG., Cipher Pharmaceuticals Inc., Vidac, Athenex, Inc., 3M, and Mayne Pharma Group Limited.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global actinic keratosis market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global actinic keratosis

Detailed Segmentation:

  • Global Actinic Keratosis Market, By Treatment:
    • Medication
    • Surgical Procedure
      • Chemical peel
      • Cryosurgery
      • Curettage and desiccation
      • Laser surgery
    • Photodynamic Therapy
    • Combination Therapies
      • Cryosurgery and PDT
      • Cryosurgery and a topical treatment
      • Topical treatments and PD
  • Global Actinic Keratosis Market, By End User:
    • Hospitals & Specialty Clinics
    • Homecare
  • Global Actinic Keratosis Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Almirall, S.A*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Bausch Health Companies Inc.
    • Perrigo Company plc
    • Sun Pharmaceutical Industries Ltd.
    • Hill Dermaceuticals, Inc.
    • Spear Pharmaceuticals
    • Tolmar Pharmaceuticals, Inc.
    • Biofrontera AG
    • Cipher Pharmaceuticals Inc.
    • Vidac
    • Athenex, Inc.
    • 3M
    • Mayne Pharma Group Limited

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global actinic keratosis market is expected to exhibit a CAGR of 4.7% during the forecast period (2022-2030).
The market is estimated to be valued at US$ 8,070.0 Mn in 2022.
Almirall, S.A., Bausch Health Companies Inc., Perrigo Company plc., Sun Pharmaceutical Industries Ltd., Hill Dermaceuticals, Inc., Spear Pharmaceuticals, Tolmar Pharmaceuticals, Inc., Bioforntera AG, Cipher Pharmaceuticals Inc., Vidac, Athenex, Inc., 3M, and Mayne Pharma Group Limited., are some of the prominent players operating in the market.
The market is expected to be valued at US$ 11,628.0 Mn in 2030.
North America is the prominent region in market
Surgical procedure, which belongs to the treatment segment, is the prominent segment in market.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo